4519 (4519) News
Track canonical SquawkNews coverage tagged to 4519, 4519. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Chugai Pharmaceutical's Pipeline Looking Increasingly Thin — Market Talk
Chugai Pharmaceutical's mid-to late-stage pipeline is looking increasingly thin, Jefferies analysts say in a note. Roche has discontinued development of GYM329 for obesity and returned the rights to Chugai. Investors hav
NEWS | Sep 29, 2026, 02:57 AM UTC
L
Roche Halts Development of Obesity Drug Candidate
By Adria CalatayudRoche Holding said it stopped work on one of its obesity-drug candidates, after clinical-trial data suggested the medicine wouldn't hit internal targets.The Swiss drugmaker said it returned rights to th
NEWS | Sep 28, 2026, 12:34 PM UTC
L
Chugai Pharmaceutical Co Ltd - Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Chugai Pharmaceutical Co Ltd TSE:4519
NEWS | Sep 28, 2026, 07:04 AM UTC